MedTrace Logo

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

NCT06818058 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-02-10

No results posted yet for this study

Summary

A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.

Conditions

  • EGFR Inhibitor-associated Rash

Interventions

DRUG

Brimonidine tartrate Gel

Once daily applications for 7 days

DRUG

Placebo gel (no Brimonidine tartrate)

Once daily applications for 7 days

Sponsors & Collaborators

  • Tarian Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-20
Primary Completion
2026-09-01
Completion
2026-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06818058 on ClinicalTrials.gov